全文获取类型
收费全文 | 63505篇 |
免费 | 4474篇 |
国内免费 | 1383篇 |
专业分类
耳鼻咽喉 | 915篇 |
儿科学 | 1860篇 |
妇产科学 | 514篇 |
基础医学 | 4334篇 |
口腔科学 | 1133篇 |
临床医学 | 9115篇 |
内科学 | 15312篇 |
皮肤病学 | 211篇 |
神经病学 | 2246篇 |
特种医学 | 3299篇 |
外国民族医学 | 7篇 |
外科学 | 11868篇 |
综合类 | 8315篇 |
现状与发展 | 4篇 |
一般理论 | 4篇 |
预防医学 | 2847篇 |
眼科学 | 414篇 |
药学 | 4034篇 |
41篇 | |
中国医学 | 1230篇 |
肿瘤学 | 1659篇 |
出版年
2024年 | 65篇 |
2023年 | 1062篇 |
2022年 | 1431篇 |
2021年 | 2563篇 |
2020年 | 2613篇 |
2019年 | 2549篇 |
2018年 | 2414篇 |
2017年 | 2038篇 |
2016年 | 1892篇 |
2015年 | 2057篇 |
2014年 | 4214篇 |
2013年 | 4096篇 |
2012年 | 3286篇 |
2011年 | 3701篇 |
2010年 | 3005篇 |
2009年 | 2898篇 |
2008年 | 3129篇 |
2007年 | 3164篇 |
2006年 | 2780篇 |
2005年 | 2498篇 |
2004年 | 2085篇 |
2003年 | 1761篇 |
2002年 | 1508篇 |
2001年 | 1402篇 |
2000年 | 1119篇 |
1999年 | 1128篇 |
1998年 | 1013篇 |
1997年 | 965篇 |
1996年 | 706篇 |
1995年 | 697篇 |
1994年 | 625篇 |
1993年 | 523篇 |
1992年 | 554篇 |
1991年 | 438篇 |
1990年 | 411篇 |
1989年 | 327篇 |
1988年 | 322篇 |
1987年 | 290篇 |
1986年 | 298篇 |
1985年 | 298篇 |
1984年 | 289篇 |
1983年 | 203篇 |
1982年 | 226篇 |
1981年 | 177篇 |
1980年 | 137篇 |
1979年 | 104篇 |
1978年 | 84篇 |
1977年 | 54篇 |
1976年 | 53篇 |
1973年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
91.
92.
Theresa M. Thole Joern Toedling Annika Sprüssel Sebastian Pfeil Larissa Savelyeva David Capper Clemens Messerschmidt Dieter Beule Stefanie Groeneveld-Krentz Cornelia Eckert Guido Gambara Anton G. Henssen Sabine Finkler Johannes H. Schulte Anja Sieber Nils Bluethgen Christian R. A. Regenbrecht Annette Künkele Marco Lodrini Angelika Eggert Hedwig E. Deubzer 《International journal of cancer. Journal international du cancer》2020,146(4):1031-1041
Accurate modeling of intratumor heterogeneity presents a bottleneck against drug testing. Flexibility in a preclinical platform is also desirable to support assessment of different endpoints. We established the model system, OHC-NB1, from a bone marrow metastasis from a patient diagnosed with MYCN-amplified neuroblastoma and performed whole-exome sequencing on the source metastasis and the different models and passages during model development (monolayer cell line, 3D spheroid culture and subcutaneous xenograft tumors propagated in mice). OHC-NB1 harbors a MYCN amplification in double minutes, 1p deletion, 17q gain and diploid karyotype, which persisted in all models. A total of 80–540 single-nucleotide variants (SNVs) was detected in each sample, and comparisons between the source metastasis and models identified 34 of 80 somatic SNVs to be propagated in the models. Clonal reconstruction using the combined copy number and SNV data revealed marked clonal heterogeneity in the originating metastasis, with four clones being reflected in the model systems. The set of OHC-NB1 models represents 43% of somatic SNVs and 23% of the cellularity in the originating metastasis with varying clonal compositions, indicating that heterogeneity is partially preserved in our model system. 相似文献
93.
Biliary tract cancer, including cholangiocarcinoma (CCA) and gallbladder cancer (GBC) are rare tumours with a rising incidence. Prognosis is poor, since most patients are diagnosed with advanced disease. Only ~20% of patients are diagnosed with early-stage disease, suitable for curative surgery. Despite surgery performed with potentially-curative intent, relapse rates are high, with around 60–70% of patients expected to have disease recurrence. Most relapses occur in the form of distant metastases, with a predominance of liver spread. In view of high tumour recurrence, adjuvant strategies have been explored for many years, in the form of radiotherapy, chemo-radiotherapy and chemotherapy. Historically, few randomised trials were available, which included a variety of additional tumours (e.g. pancreatic and ampullary tumours); most evidence relied on phase II and retrospective studies, with no high-quality evidence available to define the real benefit derived from adjuvant strategies.Since 2017, three randomised phase III clinical trials have been reported; all recruited patients with resected biliary tract cancer (CCA and GBC) who were randomised to observation alone, or chemotherapy in the form of gemcitabine (BCAT study; included patients diagnosed with extrahepatic CCA only), gemcitabine and oxaliplatin (PRODIGE-12/ACCORD-18; included patients diagnosed with CCA and GBC) or capecitabine (BILCAP; included patients diagnosed with CCA and GBC). While gemcitabine-based chemotherapy failed to show an impact on patient outcome (relapse-free survival (RFS) or overall survival (OS)), the BILCAP study showed a benefit from adjuvant capecitabine in terms of OS (pre-planned sensitivity analysis in the intention-to-treat population and in the per-protocol analysis), with confirmed benefit in terms of RFS. Based on the BILCAP trial, international guidelines recommend adjuvant capecitabine for a period of six months following potentially curative resection of CCA as the current standard of care for resected CCA and GBC. However, BILCAP failed to show OS benefit in the intention-to-treat (non-sensitivity analysis) population (primary end-point), and this finding, as well as some inconsistencies between studies has been criticised and has led to confusion in the biliary tract cancer medical community.This review summarises the adjuvant field in biliary tract cancer, with evidence before and after 2017, and comparison between the latest randomised phase III studies. Potential explanations are presented for differential findings, and future steps are explored. 相似文献
94.
95.
96.
目前化疗仍为晚期胃癌的标准治疗手段,而多数患者诊断时已接近晚期。近年新兴的免疫治疗手段程序性死亡蛋白-1(PD-1,programmed death l)抗体,通过阻断肿瘤细胞逃避自身免疫机制,重新激活自身免疫对肿瘤的杀伤作用,从而达到肿瘤的治疗作用。针对晚期胃癌的PD-1抗体治疗的临床研究已在国内外开展,大部分均有较好效果。本文对近年免疫治疗中的PD-1抗体在晚期胃癌的重要临床研究进展进行介绍。 相似文献
97.
Oral Everolimus for Treatment of a Giant Left Ventricular Rhabdomyoma in a Neonate—Rapid Tumor Regression Documented by Real Time 3D Echocardiography 下载免费PDF全文
Robert Wagner M.D. Ph.D. Frank Thomas Riede M.D. Hiroshi Seki M.D. Frauke Hornemann M.D. Steffen Syrbe M.D. Ingo Daehnert M.D. Ph.D. Michael Weidenbach M.D. Ph.D. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(12):1876-1879
The presented case reports on successful treatment with everolimus in a neonate with left ventricular giant rhabdomyoma. The authors used a different dosage regime compared to literature and documented rapid tumor regression by 3D echocardiography. 相似文献
98.
99.
100.
Sumanta K. Pal MD Dean Bajorin MD Nazli Dizman MD Jean Hoffman-Censits MD David I. Quinn MD Daniel P. Petrylak MD Matthew D. Galsky MD Ulka Vaishampayan MD Ugo De Giorgi MD Sumati Gupta MD Howard A. Burris MD Harris S. Soifer PhD Gary Li PhD Hao Wang PhD Carl L. Dambkowski MD Susan Moran MD Siamak Daneshmand MD Jonathan E. Rosenberg MD 《Cancer》2020,126(11):2597-2606